HonCode

Go Back   HER2 Support Group Forums > Breast Cancer News
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 04-03-2012, 05:08 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Antigen Express AE37 Peptide Vaccine spotlight

Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer - Tuesday, April 3, 2012

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference. The annual AACR meeting is one of the largest national cancer conferences in the US, highlighting the most significant advances in all areas of cancer research. It is being held this year from March 31 to April 4 at McCormick Place in Chicago, Il.
The specific presentation highlighted by the AACR is entitled: "Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine" by Dr. Diane Hale et al. The abstract will be available for viewing Tuesday April 3rd from 8 AM to 12 PM. The study examined patients from the controlled, randomized trial of AE37 for immunological response to the vaccine. AE37 consists of a fragment of the HER2 protein modified by proprietary means to increase potency in generating a specific immune response to HER2 expressing cancer cells. The key findings from the study are that patients receiving AE37 indeed developed a specific immune response as indicated by an increase in circulating T cells in their blood specific for the HER2 fragment as well as a positive skin test (delayed type hypersensitivity). In addition, patients receiving AE37 demonstrated a reduction in T regulatory cells, which are know to be able to hamper an immune response.
The AACR press conference was held Monday April 2nd. Dr. Hale gave a brief oral presentation of the study followed by a question and answer period.
"The finding that AE37 generates a specific immune response is consistent with the activity we've observed to date, suggesting that patients receiving the compound have a lower rate of relapse," said Dr. Elizabeth Mittendorf, senior author on the study and Principal Investigator for the trial. "These studies help us to understand at a mechanistic level how the vaccine is working and on a more general level what hallmarks to look for in developing successful cancer immunotherapy."
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.
The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes

Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"

Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla

Reconstruction: TRAM flap, partial loss, Revision

The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 02:00 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter